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To determine any differential efficacy and safety of low- vs standard-dose IV alteplase for
lacunar vs nonlacunar acute ischemic stroke (AIS), we performed post hoc analyzes from the
Enhanced Control of Hypertension and Thrombolysis Stroke Study (ENCHANTED) alte-
plase dose arm.
Methods
In a cohort of 3,297 ENCHANTED participants, we identified those with lacunar or non-
lacunar AIS with different levels of confidence (definite/according to prespecified definitions
based on clinical and adjudicated imaging findings. Logistic regression models were used to
determine associations of lacunar AIS with 90-day outcomes (primary, modified Rankin Scale
[mRS] scores 2–6; secondary, other mRS scores, intracerebral hemorrhage [ICH], and early
neurologic deterioration or death) and treatment effects of low- vs standard-dose alteplase
across lacunar and nonlacunar AIS with adjustment for baseline covariables.
Results
Of 2,588 participants with available imaging and clinical data, we classified cases as definite/
probable lacunar (n = 490) or nonlacunar AIS (n = 2,098) for primary analyses. Regardless of
alteplase dose received, lacunar AIS participants had favorable functional (mRS 2–6, adjusted
odds ratio [95% confidence interval] 0.60 [0.47–0.77]) and other clinical or safety outcomes
compared to participants with nonlacunar AIS. Low-dose alteplase (versus standard) had no
differential effect on functional outcomes (mRS 2–6, 1.04 [0.87–1.24]) but reduced the risk of
symptomatic ICH in all included participants. There were no differential treatment effects of
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Conclusions
We found no evidence from the ENCHANTED trial that low-dose alteplase had any advantages over standard dose for definite/
probable lacunar AIS.
Classification of Evidence




In routine clinical practice, patients with lacunar acute is-
chemic stroke (AIS) are eligible to receive IV thrombolysis,
given comparable favorable outcomes to other common AIS
pathologic subtypes.1–3 These results were confirmed in a
recent subgroup analysis of the Efficacy and Safety of Mag-
netic Resonance Imaging–Based Thrombolysis in Wake-Up
Stroke (WAKE-UP) trial, where the safety and efficacy of
standard-dose IV alteplase were comparable between lacunar
and nonlacunar subtypes defined on baseline MRI.4 Similar
consistency of effect of IV alteplase between lacunar and
nonlacunar AIS, defined by the Oxfordshire Community
Stroke Project (OCSP) syndromic classification, was found in
the third International Stroke Trial (IST-3).5 Despite this
evidence, some clinical concern persists over whether the
modest risk of thrombolysis-related intracerebral hemorrhage
(ICH) could offset the modest benefits of IV thrombolysis for
lacunar AIS, where the natural course is generally more benign
compared to other AIS subtypes6 from there being no or small
thrombotic lytic target on the presumption of a single pene-
trating artery occlusion.7,8
In the alteplase-dose arm of the Enhanced Control of Hy-
pertension and Thrombolysis Stroke Study (ENCHAN-
TED),9 a lower dose (0.6 mg/kg) of IV alteplase was shown
to have a lower risk of ICH compared to standard dose (0.9
mg/kg) in thrombolysis-eligible patients with AIS. Whether it
is the same for lacunar AIS is unclear. Herein, we report
further analyses of the efficacy and safety of low- vs standard-
dose IV alteplase in the ENCHANTED participants with la-
cunar (versus nonlacunar) AIS who were identified by the
combination of clinical and adjudicated imaging findings.
Methods
Primary ResearchQuestion and Evidence Level
Is there are any differential efficacy and safety of low- vs
standard-dose IV alteplase between participants with lacunar and
nonlacunar AIS in the alteplase dose arm of the ENCHANTED
trial? This study provides Class II evidence that for patients with
lacunar AIS, low-dose alteplase has no additional benefit or
safety over standard-dose alteplase.
Design and Participants
ENCHANTED was an international, multicenter, 2 × 2
quasifactorial, prospective, randomized, open-label, blinded-
endpoint trial that assessed the effectiveness of low-dose (0.6
mg/kg; 15% as bolus, 85% as infusion during 1 hour) vs
standard-dose (0.9 mg/kg; 10% as bolus, 90% as infusion
during 1 hour) IV alteplase, and more intensive vs guideline-
recommended control of blood pressure (BP) in adult
participants with AIS. The study design, participant charac-
teristics, and main results of the alteplase-dose arm have been
reported9–11 for 3,310 patients with AIS recruited from 111
centers in 13 countries. Key demographic and clinical char-
acteristics were recorded at the time of enrollment, with
clinical severity defined according to the NIH Stroke Scale
(NIHSS) at baseline, 24 hours, and at day 7 (or on discharge
from hospital if earlier). A final clinical diagnosis of AIS
subtypes based upon the opinion of site investigations, gen-
erally according to the Trial of Org 10172 in Acute Stroke
Treatment (TOAST) classification system,12 was made at
day 7, postrandomization (or on discharge from hospital, if
earlier).
Glossary
AIS = acute ischemic stroke; BP = blood pressure; CI = confidence interval; CSVD = cerebral small vessel disease; CTA = CT
angiography;DICOM =Digital Imaging and Communications inMedicine; ECASS = European–Australian Cooperative Acute
Stroke Study; ENCHANTED = Enhanced Control of Hypertension and Thrombolysis Stroke Study; END = early neurologic
deterioration; ICH = intracerebral hemorrhage; IST-3 = the third International Stroke Trial; LVO = large vessel occlusion;
MRA = magnetic resonance angiography; mRS = modified Rankin Scale; NIHSS = NIH Stroke Scale; NINDS = National
Institutes of Neurological Diseases and Stroke; OCSP = Oxfordshire Community Stroke Project; OR = odds ratio; sICH =
symptomatic intracerebral hemorrhage; SITS-MOST = the Safe Implementation of Thrombolysis in Stroke–Monitoring Study;
TICI = Thrombolysis in Cerebral Infarction; TOAST = Trial of Org 10172 in Acute Stroke Treatment classification;WAKE-
UP = Efficacy and Safety of MRI-based Thrombolysis in Wake-Up Stroke trial.
Neurology.org/N Neurology | Volume 96, Number 11 | March 16, 2021 e1513
Standard Protocol Approvals, Registrations,
and Participant Consents
The study protocol was approved by the appropriate ethics
committee at each participating center and written informed
consent was obtained from participants or an appropriate
legal surrogate according to the Declaration of Helsinki. The
ENCHANTED trial was registered at ClinicalTrials.gov
(Unique identifier: NCT01422616).
Imaging Analysis
Uncompressed digital images of all baseline and follow-up
digital CT, MRI, and angiographic images were uploaded into
the study brain imaging database in Digital Imaging and
Communications in Medicine (DICOM) format identified
only by the participant’s unique study identification number.
Images were analyzed centrally for any ICH by a trial adjudi-
cation panel, blind to clinical data, treatment, date, and se-
quence of scan. Assessors graded any identified symptomatic
ICH (sICH) using a range of standard definitions from the Safe
Implementation of Thrombolysis in Stroke–Monitoring Study
(SITS-MOST), National Institute of Neurologic Disease and
Stroke (NINDS), the European–Australian Cooperative Acute
Stroke Study II (ECASS), ECASS III, and IST-3 (additional
Methods I, doi.org/10.5061/dryad.t1g1jwt0s).
The ENCHANTED Imaging Analysis Project was established
in August 2016, with the aim of defining the presence, extent,
and severity of, and swelling from, acute ischemic changes
(including arterial territory, border zone, small subcortical and
brainstem/cerebellar infarcts), coexisting old vascular lesions
and their subtypes, white matter lesions, and brain volume loss
on all collected images by an imaging analysis team of trained
individuals, blind to all clinical data, using an electronic scoring
system modified from IST-3.13 All observed infarct lesions on
baseline (prerandomization) CT or MRI were coded according
to the IST-3 criteria for infarct site and size. Separately and
subsequent to primary scan reads, a neuroradiologist (Z.Z.) and
neurosurgeon (X.C.) sought the ischemic lesion on 24-hour
follow-up images while viewing the baseline images for those
with no infarct lesion identified at baseline. They also assessed
large vessel occlusion (LVO) on baseline CT angiography
(CTA) or magnetic resonance angiography (MRA) according
to a modified Thrombolysis in Cerebral Infarction (TICI) score
for an abnormal artery in IST-3.14 All the imaging data were
cross-checked (Z.Z.) and a final rating made before unmasking
the clinical data and randomization code for analyses.
Definitions of Lacunar and Nonlacunar AIS
Different levels of confidence (definite/probable/possible)
were used around the definitions of lacunar and nonlacunar
AIS based on adjudicated imaging findings, clinical severity,
and clinical diagnosis (additional Methods II, doi.org/10.
5061/dryad.t1g1jwt0s). In brief, definite lacunar AIS was
defined when all 4 criteria were met: (1) the presence of acute
infarct lesion (maximum diameter ≤20 mm) in the territory of
penetrating arteries, with a rounded, ovoid, or tubular shape
on axial CT or diffusion-weighted imaging/apparent diffusion
coefficient map (typical examples are shown in figure 1)15; (2)
no LVO adjudicated centrally (on CTA/MRA) or reported
by site investigators (on CTA/MRA/digital subtraction an-
giography); (3) the final diagnosis was reported as “small
vessel or perforating vessel ‘lacunar’ disease” according to the
TOAST criteria that involved any of the standard clinical
lacunar syndromes with the lack of large vessel atheroma or
cerebral cortical dysfunction; and (4) infarct side on images is
consistent with that reported by site investigators. Definite
nonlacunar AIS was defined as having acute infarct lesion with
maximum diameter >20 mm or LVO on angiography. Par-
ticipants were classified as nonlacunar if they had lacunar and
nonlacunar infarcts.
Given that the clinical diagnosis of lacunar syndrome plus
baseline NIHSS score <7 had a high specificity to predict
imaging-confirmed lacunar stroke in IST-3,16 probable lacu-
nar and nonlacunar AIS were discriminated mainly by base-
line NIHSS scores and final diagnosis in the situation that
there was no acute infarct lesion identified on images or the
images were not collected from the sites. For those with
conflicting clinical and adjudicated imaging information that
compromised the confidence of discrimination, we classified
as possible lacunar or nonlacunar AIS according to the clinical
diagnosis and LVO status.
Outcomes
The primary outcome of these analyses was the composite
endpoint of disability or death (modified Rankin Scale [mRS]
scores 2–6) at 90 days postrandomization. Secondary efficacy
outcomes included major disability or death (mRS 3–6),
death (mRS 6), and ordinal shift of the full range of mRS
scores at 90 days. Secondary safety outcomes were sICH
defined according to several criteria from other studies, fatal
ICHwithin 7 days, ICH identified by central adjudicators, and
any ICH adjudicated centrally or reported by site investiga-
tors. Other clinical outcomes included early neurologic de-
terioration (END) (≥4-point increase in NIHSS scores) or
death within 24 hours or 7 days.
Statistical Analysis
Continuous or categorical variables at baseline were presented
as mean (SD), median (interquartile range), or number (per-
centage). Baseline differences between participants with lacu-
nar and nonlacunar AIS were evaluated using analysis of
variance, χ2 test, or Wilcoxon signed-rank test, as appropriate.
Associations of lacunar AIS with 90-day function, safety, and
other secondary outcomes were estimated in logistic regression
models with adjustment for randomized treatment and key
prognostic covariates (age, sex, ethnicity, baseline NIHSS
score, time from symptom onset to randomization, premorbid
function [mRS score 0 or 1], prior use of antithrombotic
agents, history of diabetes or cardiovascular disease, and
assigned to intensive blood pressure–lowering group). The
treatment effect of low- vs standard-dose alteplase was de-
termined in logistic regression models and the heterogeneity of
alteplase dose effect across participants with lacunar and
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nonlacunar AIS was estimated by adding an interaction term to
statistical models. Proportional odds regression models were
used to analyze ordinal mRS scores. The primary analyses
pertain to participants with definite/probable lacunar and
nonlacunar AIS after excluding those with a possible diagnostic
classification. Sensitivity analyses of the treatment effects of
low- vs standard-dose alteplase were performed in participants
with definite lacunar/nonlacunar AIS and in all participants
with possible lacunar/nonlacunar AIS. We also performed an
exploratory analysis of the treatment effects in a subset of la-
cunar AIS identified at baseline (infarct size ≤15 mm and no
adjudicated LVO). Data were reported as odds ratios (ORs)
and 95% confidence intervals (CIs) and a 2-sided p < 0.05 was
considered statistically significant. All analyses were performed
using SAS version 7.1 and Stata version 12.0.
Data Availability
Additional methods (I and II) and data (supplementary tables
1–3) are available from Dryad (doi.org/10.5061/dryad.
t1g1jwt0s). Individual de-identified participant data used in this
analysis will be shared by request from any qualified investigator
via the ResearchOffice of TheGeorge Institute forGlobalHealth.
Results
Baseline Characteristics
Among 3,297 AIS participants in the ENCHANTED alteplase
dose arm, 2,588 (78.5%) were classifiable (definite lacunar,
n = 195; probable lacunar, n = 295; definite nonlacunar, n =
1,697; and probable nonlacunar, n = 401 AIS) for inclusion in
Figure 1 Examples of Lacunar Ischemic Stroke at Different Locations From ENCHANTED
Lacunar stroke at (A) left lentiform (red arrow) identified on 24-hour follow-up CT; (B) left internal capsule (red arrow) identified on 24-hour follow-upMRI; (C)
right centrum semiovale (red arrow) identified on baseline and 24-hour follow-upMRI; (D) left internal border zone (red arrow) identified on baseline MRI; (E)
right thalamus (red arrow) identified onbaseline and 24-hour follow-upCT; and (F) brainstem (red arrow) identified on 24-hour follow-upMRI. DWI =diffusion-
weighted imaging; ENCHANTED = Enhanced Control of Hypertension and Thrombolysis Stroke Study.
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the primary analysis (figure 2). Compared to the 709 excluded
participants, they were more likely to be older, have higher
baseline NIHSS scores, be Asian, have a history of cardio-
vascular disease, and have a final diagnosis of LVO, but they
also had shorter time interval from symptom onset to ran-
domization (supplementary table 1, doi.org/10.5061/dryad.
t1g1jwt0s). Table 1 shows that all the baseline clinical char-
acteristics were significantly different between definite/
probable lacunar and nonlacunar AIS except for sex, history
of diabetes, and prior use of statin/other lipid-lowering
agents. Participants with lacunar (versus nonlacunar) AIS
were younger and had milder neurologic impairment, higher
baseline BP, and a lower proportion with conventional car-
diovascular risk factors except smoking. In keeping with the
lacunar pattern of stroke, few participants had multiple lesions
in both anterior and posterior circulation, but they were more
likely to have a lesion only in the posterior circulation. They
were also less likely to have brain atrophy or a hyperdense
vessel sign on CT or hyperintense arteries on MRI.
Lacunar AIS and Outcomes
Compared to participants with definite/probable nonlacunar
AIS, those with definite/probable lacunar AIS had better 90-
day functional outcomes, whether defined by the outcome of
mRS scores 2–6 (unadjusted OR 0.26, 95% CI 0.21–0.33),
mRS scores 3–6 (0.20, 0.15–0.26), ordinal shift in the full range
of scores (0.27, 0.23–0.33), or death alone (0.04, 0.01–0.12)
(table 2). They were also less likely to have ICH and END or
death after IV thrombolysis. The findings persisted with ad-
justment of baseline covariables and randomized alteplase dose.
Lacunar AIS and Alteplase Dose
The overall treatment effects of low- vs standard-dose alte-
plase on function, safety, and other outcomes in these 2,588
participants were comparable to the main results of the
ENCHANTED trial, that low-dose vs standard-dose alteplase
reduced the risk of sICH (SITS-MOST criteria, adjusted OR
0.39, 95% CI 0.21–0.73; NINDS criteria, 0.67, 0.50–0.89;
ECASS II criteria, 0.56, 0.39–0.80; ECASS III criteria, 0.37,
0.21–0.67; IST-3 criteria, 0.54, 0.33–0.87) but with no dif-
ference in effect on functional outcomes (mRS 2–6, adjusted
OR 1.04, 95% CI 0.87–1.24; mRS 3–6, 1.01, 0.85–1.21).
There was no heterogeneity of treatment effects on all out-
comes for definite/probable lacunar vs nonlacunar AIS after
adjustment for baseline covariables (all pinteraction ≥0.07)
(figures 3 and 4). Similar results were seen in the sensitivity
analyses for definite lacunar and nonlacunar AIS (all pinteraction
≥0.16) (figures 4 and 5) and definite/probable/possible la-
cunar and nonlacunar AIS (all pinteraction ≥0.12) (data avail-
able on request).
Specifically, in the definite subgroup of lacunar AIS, there
were no significant differences on the primary efficacy out-
come (mRS 2–6) (33.7% vs 32.9%, adjusted OR 0.96, 95% CI
0.49–1.87) or major disability or death (mRS 3–6) (20.2% vs
15.3%, adjusted OR 1.31, 95% CI 0.54–3.19) between low-
dose and standard-dose alteplase groups (figure 5). There was
one case of sICH (0.9%) meeting NINDS and IST-3 criteria
in participants with definite lacunar AIS treated by low-dose
alteplase, but no case of sICH was observed after use of
standard-dose alteplase. In participants with definite lacunar
Figure 2 Flowchart of Participants Included in Analyses
Def/Pro = definite or probable.
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Table 1 Baseline Characteristics of Participants With Definite/Probable Lacunar and Nonlacunar Stroke
Low-dose: LACS (n = 241),
nonlacunar stroke (n = 1,059)
Standard-dose: LACS (n = 249),
nonlacunar stroke (n = 1,039)






LACS 63.9 (12.8) 63.1 (12.5) 63.5 (12.7) <0.001b
Nonlacunar stroke 67.8 (12.7) 67.8 (12.6) 67.8 (12.7)
Female
LACS 82 (34.0) 91 (36.5) 173 (35.3) 0.31
Nonlacunar stroke 402 (38.0) 390 (37.5) 792 (37.8)
Asian ethnicity
LACS 179 (74.3) 174 (69.9) 353 (72.0) <0.001b
Nonlacunar stroke 675 (63.7) 663/1,038 (63.9) 1,338/2097 (63.8)
Clinical features
Systolic BP, mm Hg
LACS 151.6 (17.8) 153.7 (19.4) 152.6 (18.7) <0.001b
Nonlacunar stroke 148.0 (19.7) 148.3 (20.2) 148.2 (19.9)
Diastolic BP, mm Hg
LACS 86.6 (11.7) 86.7 (12.9) 86.6 (12.3) <0.001b
Nonlacunar stroke 84.0 (13.2) 84.2 (13.0) 84.1 (13.1)
Heart rate, beats per minute
LACS 76.1 (11.7) 77.7 (12.7) 76.9 (12.2) 0.001b
Nonlacunar stroke 79.3 (16.6) 79.7 (16.3) 79.5 (16.5)
NIHSS scorec
LACS 4 (3–6) 5 (4–6) 5 (3–6) <0.001b
Nonlacunar stroke 11 (7–16) 11 (7–16) 11 (7–16)
GCS scored
LACS 15 (15–15) 15 (15–15) 15 (15–15) <0.001b
Nonlacunar stroke 14 (12–15) 15 (12–15) 15 (12–15)
Medical history
Previous stroke
LACS 39 (16.2) 30 (12.0) 69 (14.1) 0.03b
Nonlacunar stroke 185 (17.5) 197 (19.0) 382 (18.2)
Hypertension
LACS 142 (58.9) 148 (59.4) 290 (59.2) 0.03b
Nonlacunar stroke 671 (63.4) 678/1,038 (65.3) 1,349/2097 (64.3)
Atrial fibrillation
LACS 9 (3.7) 11 (4.4) 20 (4.1) <0.001b
Nonlacunar stroke 288/1,056 (27.3) 259/1,038 (25.0) 547/2094 (26.1)
Coronary artery disease
LACS 23 (9.5) 16 (6.4) 39 (8.0) <0.001b
Continued
Neurology.org/N Neurology | Volume 96, Number 11 | March 16, 2021 e1517
Table 1 Baseline Characteristics of Participants With Definite/Probable Lacunar and Nonlacunar Stroke (continued)
Low-dose: LACS (n = 241),
nonlacunar stroke (n = 1,059)
Standard-dose: LACS (n = 249),
nonlacunar stroke (n = 1,039)





Nonlacunar stroke 184 (17.4) 171/1,038 (16.5) 355/2097 (16.9)
Valvular/other heart disease
LACS 4 (1.7) 7 (2.8) 11 (2.2) <0.001b
Nonlacunar stroke 92 (8.7) 95/1,038 (9.2) 187/2097 (8.9)
Diabetes
LACS 50 (20.7) 52 (20.9) 102 (20.8) 0.59
Nonlacunar stroke 203 (19.2) 211/1,038 (20.3) 414/2097 (19.7)
Hypercholesterolemia
LACS 34 (14.1) 32 (12.9) 66 (13.5) 0.04b
Nonlacunar stroke 194 (18.3) 171/1,038 (16.5) 365/2097 (17.4)
Current smoker
LACS 63 (26.1) 85 (34.1) 148 (30.2) <0.001b
Nonlacunar stroke 222/1,057 (21.0) 233/1,037 (22.5) 455/2094 (21.7)
Prestroke function without
disabilitye
LACS 36 (14.9) 33 (13.3) 69 (14.1) 0.005b
Nonlacunar stroke 194/1,058 (18.3) 216/1,037 (20.8) 410/2095 (19.6)
Medication on admission
Antihypertensive agents
LACS 93 (38.6) 103 (41.4) 196 (40.0) 0.002b
Nonlacunar stroke 507 (47.9) 496/1,038 (47.8) 1,003/2097 (47.8)
Warfarin anticoagulation
LACS 1/240 (0.4) 1 (0.4) 2/489 (0.4) <0.001b
Nonlacunar stroke 39 (3.7) 29/1,037 (2.8) 68/2096 (3.2)
Aspirin/other antiplatelet
agent
LACS 46/240 (19.2) 47 (18.9) 93/489 (19.0) 0.01b
Nonlacunar stroke 287 (27.1)f 225/1,037 (21.7)f 512/2096 (24.4)
Statin/other lipid-lowering
agent
LACS 40/240 (16.7) 38 (15.3) 78/489 (16.0) 0.11
Nonlacunar stroke 215/1,058 (20.3) 185/1,037 (17.8) 400/2095 (19.1)
Time from stroke onset to
CT/MRI scan, h
LACS 1.8 (1.3–2.5) 1.9 (1.3–2.6) 1.8 (1.3–2.5) <0.001b
Nonlacunar stroke 1.7 (1.1–2.3) 1.6 (1.1–2.3) 1.6 (1.1–2.3)
Imaging features
Infarct at left side
LACS 78/153 (51.0) 78/150 (52.0) 156/303 (51.5) 0.14
Continued
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Table 1 Baseline Characteristics of Participants With Definite/Probable Lacunar and Nonlacunar Stroke (continued)
Low-dose: LACS (n = 241),
nonlacunar stroke (n = 1,059)
Standard-dose: LACS (n = 249),
nonlacunar stroke (n = 1,039)





Nonlacunar stroke 400/841 (47.6) 384/833 (46.1) 784/1,674 (46.8)
Infarct at right side
LACS 70/153 (45.8) 66/150 (44.0) 136/303 (44.9) 0.11
Nonlacunar stroke 407/841 (48.4) 428/833 (51.4) 835/1,674 (49.9)
Infarct at midline or bilateral
side
LACS 5/153 (3.3) 6/150 (4.0) 11/303 (3.6) 0.76
Nonlacunar stroke 34/841 (4.0) 21/833 (2.5) 55/1,674 (3.3)
Infarct in anterior circulation
only
LACS 117/153 (76.5) 114/150 (76.0) 231/303 (76.2) 0.09
Nonlacunar stroke 689/841 (81.9) 658/833 (79.0) 1,347/1,674 (80.5)
Infarct in posterior circulation
only
LACS 35/153 (22.9) 36/150 (24.0) 71/303 (23.4) <0.001b
Nonlacunar stroke 103/841 (12.2) 120/833 (14.4) 223/1,674 (13.3)
Infarct in anterior and posterior
circulation
LACS 1/153 (0.7) 0/150 (0.0) 1/303 (0.3) <0.001b
Nonlacunar stroke 49/841 (5.8) 55/833 (6.6) 104/1,674 (6.2)
With FLAIR-HAs or hyperdense
vessel sign
LACS 3/151 (2.0) 5/156 (3.2) 8/307 (2.6) <0.001b
Nonlacunar stroke 306/835 (36.6) 305/826 (36.9) 611/1,661 (36.8)
With old vascular lesions
LACS 70/153 (45.8) 59/150 (39.3) 129/303 (42.6) 0.83
Nonlacunar stroke 362/841 (43.0) 362/833 (43.5) 724/1,674 (43.2)
With brain atrophy
LACS 94/153 (61.4) 79/150 (52.7) 173/303 (57.1) <0.001b
Nonlacunar stroke 574/841 (68.3) 589/833 (70.7) 1,163/1,674 (69.5)
With white matter changes
LACS 64/153 (41.8)f 46/150 (30.7)f 110/303 (36.3) 0.82
Nonlacunar stroke 301/841 (35.8) 318/833 (38.2) 619/1,674 (37.0)
Site reported LVO or assessed
centrally
LACS 0 (0.0) 0 (0.0) 0 (0.0) <0.001b
Nonlacunar stroke 270/1,041 (25.9) 262/1,027 (25.5) 532/2068 (25.7)
Time from stroke onset to
randomization, h
LACS 3.0 (2.3–3.7) 2.8 (2.2–3.6) 2.9 (2.2–3.6) <0.001b
Continued
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AIS who received low-dose alteplase, 3 (2.8%) had adjudi-
cated ICH and 1 more had ICH reported by a site in-
vestigator, while any ICH occurred in 2 (2.2%) participants
with definite lacunar AIS assigned to the standard-dose group.
In a smaller subset of definite lacunar AIS identified at baseline
with size <15 mm and no adjudicated LVO, 4 of the 9 par-
ticipants (44.4%) in the low-dose group and 2 of the 7 par-
ticipants (28.6%) in the standard-dose group had mRS 2–6 at
90 days postrandomization, and no ICH occurred in either
treatment group (supplementary table 2, doi.org/10.5061/
dryad.t1g1jwt0s).
Discussion
In these post hoc analyzes of the ENCHANTED trial, we did not
identify any benefit, nor any harm, from the use of low-dose
alteplase vs standard-dose alteplase to treat patients with lacunar
AIS compared to those with other subtypes of AIS. As well as
having a range of significantly different characteristics, the 90-day
outcomes were better for those with lacunar than nonlacunar
AIS, which provided some internal consistency for the classifi-
cations used in our study. However, given the low event rate of
sICH,with fewer than 5 events in the primary analysis for definite
or probable lacunar AIS, we are limited in the conclusions that
can be drawn as towhether a lower dose of IV alteplase should be
preferred because of the good prognosis for lacunar AIS.
Our results on thrombolysis outcomes for lacunar AIS are
consistent with prior observational studies.2,17–21 However,
the net benefit of thrombolysis for lacunar AIS is still debated,
mainly because the evidence is drawn from subgroup analyzes
of trials, such as WAKE-UP4 and IST-3,5 where there is low
statistical power. In addition, accurate identification of lacunar
AIS is challenging, especially in the absence of an acute lesion
on the initial CT, and even MRI (in nearly one third of
patients with nondisabling stroke).22 The pragmatic approach
of applying a lacunar syndrome classification system in studies
has moderate diagnostic sensitivity and specificity,15 which
may potentially mix patients with nonlacunar AIS with the
target population of lacunar AIS, and nondifferentially bias
results towards IV thrombolysis.
We were unable to confirm in ENCHANTED participants
any benefit of low-dose over standard-dose alteplase in lacu-
nar AIS. The fact that there were few cases of sICH in the low-
dose alteplase group, and no sICH in the standard-dose
group, highlights the potential for chance and imprecise es-
timates of treatment effects when there are few events. Even
with current imaging techniques and clinical criteria, it is
difficult to discriminate lacunar AIS due to occlusion of a deep
penetrating arteriole presumed caused by progressive lip-
ohyalinosis from thrombosis related to atherosclerosis or
embolus. Platelet activation triggered by disintegration of the
endothelium from intrinsic cerebral small vessel disease
(CSVD) may also be relevant in this type of AIS.8 It is pos-
sible, therefore, that IV thrombolysis may have a differential
effect dependent on the cause of lacunar stroke, being more
effective when there is underlying thromboembolism. In la-
cunar AIS, we noted a significant imbalance in the frequency
of background white matter lesions between the low-dose and
standard-dose alteplase groups (41.8% vs 30.7%), which
could partly account for more ICH in the former (supple-
mentary table 3, doi.org/10.5061/dryad.t1g1jwt0s).23 Again,
however, due to the few sICH events in patients with lacunar
AIS, we cannot confirm whether the increase in sICH by low-
dose alteplase was confounded by CSVD.
Table 1 Baseline Characteristics of Participants With Definite/Probable Lacunar and Nonlacunar Stroke (continued)
Low-dose: LACS (n = 241),
nonlacunar stroke (n = 1,059)
Standard-dose: LACS (n = 249),
nonlacunar stroke (n = 1,039)





Nonlacunar stroke 2.6 (1.9–3.3) 2.6 (1.9–3.4) 2.6 (1.9–3.4)
Assigned to intensive BP lowering
LACS 48 (19.9) 48 (19.3) 96 (19.6) <0.001b
Nonlacunar stroke 127 (12.0) 139 (13.4) 266 (12.7)
Assigned to standard BP lowering
LACS 41 (17.0) 48 (19.3) 89 (18.2) 0.008b
Nonlacunar stroke 145 (13.7) 138 (13.3) 283 (13.5)
Abbreviations: BP = blood pressure; FLAIR = fluid-attenuated inversion recovery; GCS = Glasgow Coma Scale; HAs = hyperintense arteries; LACS = lacunar
stroke; LVO = large vessel occlusion; NIHSS = NIH Stroke Scale.
Data are n (%), mean (SD), or median (Q1, Q3). The p values are based on χ2, analysis of variance, or Wilcoxon signed-rank test.
a Total lacunar stroke vs total nonlacunar stroke.
b Significant.
c Scores on the NIHSS range from 0 to 42, with higher scores indicating more severe neurologic deficits.
d Scores on the GCS range from 15 (normal) to 3 (deep coma).
e mRS = 0.
f p < 0.05 by randomization treatment.
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Some strengths of our study include the large, prospective,
multicenter cohort of patients with AIS who had systematic,
complete, and high-quality data collected prospectively, where we
were able to adjust for multiple covariables in statistical models.
Furthermore, the imaging assessment was completed blind to
clinical features and other data, using a rigorously defined ap-
proach developed for the IST-3 study. However, we acknowledge
limitations that include insufficient statistical power and
inevitable selection bias from the data being derived from a
clinical trial where a large number of participants were from Asia
and had mild to moderate stroke. Moreover, given the pragmatic
nature of ENCHANTED, few participants had a baseline brain
MRI, and the identification of lacunar AIS required analysis of
follow-up images with comparison to those obtained at baseline.
Whereas this approachmay have altered the imaging appearances
of acute ischemic lesions after use of IV thrombolysis24 and
Table 2 Thrombolysis Outcomes in Definite/Probable Lacunar Versus Nonlacunar Stroke
Lacunar, n/N (%) Nonlacunar, n/N (%)
Lacunar vs nonlacunar stroke
OR (95% CI)a p Value aOR (95% CI)a,b p Value
90-day functional outcomes
mRS 2–6 147/481 (30.6) 1,284/2052 (62.6) 0.26 (0.21, 0.33) <0.001c 0.60 (0.47, 0.77) <0.001c
mRS 3–6 75/481 (15.6) 987/2052 (48.1) 0.20 (0.15, 0.26) <0.001c 0.51 (0.38, 0.69) <0.001c
mRS 6 3/490 (0.6) 282/2098 (13.4) 0.04 (0.01, 0.12) <0.001c 0.13 (0.04, 0.43) <0.001c
mRS 0 185/481 (38.5) 370/2052 (18.0) 0.27 (0.23, 0.33) <0.001c 0.64 (0.52, 0.78) <0.001c
1 149/481 (31.0) 398/2052 (19.4)
2 72/481 (15.0) 297/2052 (14.5)
3 47/481 (9.8) 278/2052 (13.5)
4 21/481 (4.4) 265/2052 (12.9)
5 4/481 (0.8) 162/2052 (7.9)
6 3/481 (0.6) 282/2052 (13.7)
Safety outcomes (sICH or ICH)
SITS-MOST 1/490 (0.2) 48/2098 (2.3) 0.09 (0.01, 0.63) 0.02c 0.09 (0.01, 0.70) 0.02c
NINDS 4/490 (0.8) 211/2098 (10.1) 0.07 (0.03, 0.20) <0.001c 0.10 (0.04, 0.27) <0.001c
ECASS II 2/490 (0.4) 132/2098 (6.3) 0.06 (0.02, 0.25) <0.001c 0.08 (0.02, 0.31) <0.001c
ECASS III 1/490 (0.2) 57/2098 (2.7) 0.07 (0.01, 0.53) 0.01c 0.08 (0.01, 0.58) 0.01c
IST-3 2/490 (0.4) 74/2098 (3.5) 0.11 (0.03, 0.46) 0.002c 0.13 (0.03, 0.54) 0.005c
Fatal ICH 0/490 (0.0) 32/2098 (1.5) — — — —
Adjudicated any ICH 17/490 (3.5) 524/2098 (25.0) 0.11 (0.07, 0.18) <0.001c 0.18 (0.11, 0.29) <0.001c
Any ICH 18/490 (3.7) 582/2098 (27.7) 0.10 (0.06, 0.16) <0.001c 0.16 (0.10, 0.27) <0.001c
Other secondary outcomes
END or death
Within 24 h 20/490 (4.1) 216/2098 (10.3) 0.37 (0.23, 0.59) <0.001c 0.30 (0.18, 0.50) <0.001c
Within 7 d 27/490 (5.5) 336/2098 (16.0) 0.31 (0.20, 0.46) <0.001c 0.36 (0.24, 0.56) <0.001c
Abbreviations: aOR = adjusted odds ratio; CI = confidence interval; ECASS = European–Australian Cooperative Acute Stroke Study; END = early neurologic
deterioration; ICH = intracerebral hemorrhage; IST-3 = third International Stroke Trial; mRS = modified Rankin Scale; NIHSS = NIH Stroke Scale; NINDS =
National Institutes of Neurologic Diseases and Stroke; OR = odds ratio; sICH = symptomatic intracerebral hemorrhage; SITS-MOST = Safe Implementation of
Thrombolysis in Stroke–Monitoring Study.
a Refers to the effect of IV thrombolysis in definite/probable lacunar stroke vs nonlacunar stroke after pooling the 2 groups of randomized alteplase dose as
one cohort.
b Adjusted for key prognostic covariates (age, sex, ethnicity, baseline NIHSS score, time from stroke onset to randomization, premorbid function [mRS score
0 or 1], prior use of antithrombotic agents [aspirin, other antiplatelet agent, or warfarin], history of diabetes or cardiovascular disease [stroke, atrial
fibrillation, coronary artery disease, valvular or other heart disease], assigned to intensive blood pressure–lowering group, and randomization to low-dose
alteplase group) for functional outcomes. Adjusted for minimization and key prognostic covariates (age, baseline NIHSS score, time from stroke onset to
randomization, assigned to intensive blood pressure–lowering group, and randomization to low-dose alteplase group) for safety outcomes and neurologic
deterioration within 24 hours and 7 days.
c Significant.
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Figure 3 Thrombolysis Outcomes in Participants With Definite/Probable Lacunar and Nonlacunar Stroke by Randomized
Treatment
*Adjusted for key prognostic covariates (age, sex, ethnicity, baseline NIH Stroke Scale [NIHSS] score, time from stroke onset to randomization, premorbid
function [modified Rankin Scale (mRS) scores 0 or 1], prior use of antithrombotic agents [aspirin, other antiplatelet agent, or warfarin], history of diabetes or
cardiovascular disease [stroke, atrial fibrillation, coronary artery disease, valvular or other heart disease], assigned to intensive blood pressure–lowering
group) for functional outcomes. Adjusted for minimization and key prognostic covariates (age, baseline NIHSS score, time from stroke onset to randomi-
zation, and assigned to intensive blood pressure–lowering group) for safety outcomes and neurologic deterioration within 24 hours or 7 days.†Site reported
or adjudicated centrally. CI = confidence interval; ECASS = European–Australian Cooperative Acute Stroke Study; END = early neurologic deterioration; ICH =
intracerebral hemorrhage; IST-3 = third International Stroke Trial; NINDS = National Institutes of Neurologic Diseases and Stroke; sICH = symptomatic
intracerebral hemorrhage; SITS-MOST = Safe Implementation of Thrombolysis in Stroke–Monitoring Study.
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limited the identification of all true lacunar AIS, our results are
comparable with previous work showing that nearly one-third of
patients with nondisabling AIS lack an infarct lesion on acute
MRI (median 4 days poststroke).22 In the ENCHANTED alte-
plase arm, 27.1% (789/2,916) of participants had no infarct lesion
on either the baseline or 24-hour follow-up images. Thus, we had
to use a combination of clinical and adjudicated imaging data to
classify asmany cases as possible into lacunar and nonlacunar AIS,
which likely closely represents that used in routine practice.
Relatively small samples in lacunar AIS compromised the power
of a reliable assessment of any interaction, especially for sICH.
Moreover, regarding the outcomes of major disability or death, a
pinteraction of 0.07 might have been due to chance rather than true
differential treatment effects of low- vs standard-dose alteplase
across definite/probable lacunar and nonlacunar AIS. Future
research in systematic reviews and clinical registries may be re-
quired to confirm or refute these findings.
We found no clear evidence that low-dose IV alteplase was
any better or safer than standard-dose alteplase in the
Figure 4 Randomized Treatment Effects on the Ordinal Modified Rankin Scale (mRS) Score by Lacunar and Nonlacunar
Stroke
*Adjusted for key prognostic covariates (age, sex, ethnicity, baseline NIH Stroke Scale [NIHSS] score, time from stroke onset to randomization, premorbid
function [mRS scores 0 or 1], prior use of antithrombotic agents [aspirin, other antiplatelet agent, or warfarin], history of diabetes or cardiovascular disease
[stroke, atrial fibrillation, coronary artery disease, valvular or other heart disease], assigned to intensive blood pressure–lowering group).
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Figure 5 Thrombolysis Outcomes in Participants With Definite Lacunar and Nonlacunar Stroke by Randomized Treatment
*Adjusted for key prognostic covariates (age, sex, ethnicity, baseline NIH Stroke Scale [NIHSS] score, time from stroke onset to randomization, premorbid
function [modified Rankin Scale (mRS) scores 0 or 1], prior use of antithrombotic agents [aspirin, other antiplatelet agent, or warfarin], history of diabetes or
cardiovascular disease [stroke, atrial fibrillation, coronary artery disease, valvular or other heart disease], assigned to intensive blood pressure–lowering
group) for functional outcomes. Adjusted for minimization and key prognostic covariates (age, baseline NIHSS score, time from stroke onset to randomi-
zation, and assigned to intensive blood pressure–lowering group) for safety outcomes and neurologic deterioration within 24 hours or 7 days. †Site reported
or adjudicated centrally. CI = confidence interval; ECASS = European–Australian Cooperative Acute Stroke Study; END = early neurologic deterioration; ICH =
intracerebral hemorrhage; IST-3 = third International Stroke Trial; NINDS = National Institutes of Neurologic Diseases and Stroke; sICH = symptomatic
intracerebral hemorrhage; SITS-MOST = Safe Implementation of Thrombolysis in Stroke–Monitoring Study.
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ENCHANTED participants who had lacunar AIS. According
to standard eligibility criteria, patients with lacunar AIS should
receive standard dose IV alteplase as with other AIS subtypes.
Acknowledgment
The authors thank the investigators, study teams, and patients
for participating in the ENCHANTED trial. The research
team acknowledges the support of the National Institute for
Health Research Clinical Research Network (NIHR CRN)
for conduct of the trial in England. Z.Z. received overseas
visiting funding from Ren Ji Hospital, School of Medicine,
Shanghai Jiao Tong University (2016–2018) and a Scientia
PhD Scholarship from the University of New South Wales,
Sydney (2018–2022) during the conduct of the study. C.S.A.
holds an NHMRC Senior Investigator Fellowship.
Study Funding
This study is supported by grants from the National Health
and Medical Research Council (NHMRC) of Australia
(project grant numbers 1020462 and 1101113), the Stroke
Association of the UK (TSA 2012/01 and 2015/01), the
Ministry of Health and the National Council for Scientific and
Technological Development of Brazil (CNPQ: 467322/
2014-7, 402388/2013-5), the Ministry for Health, Welfare
and Family Affairs of the Republic of Korea (HI14C1985)
(for the alteplase-dose arm), and a research grant from
Takeda for conduct of the study in China.
Disclosure
Dr. Xia received a scholarship from China Scholarship Council
(CSC). Prof. Hackett reports a fellowship and research grants
from the National Health and Medical Research Council
(NHMRC) of Australia. Prof. Woodward reports a National
Health and Medical Research Council Investigator Grant
(APP1174120) and Program Grant (APP1149987) and is a
consultant to Amgen, Freeline, and Kyowa Hakko Kirin. Prof.
Chalmers reports research grants and honoraria from Servier for
the ADVANCE trial, outside the submitted work. Prof. Rob-
inson reports grants from The Stroke Association, UK, and was
a National Institute for Health Research (NIHR) Senior In-
vestigator during the conduct of the study. Prof. Parsons reports
personal fees from serving on Advisory Board for Boehringer
Ingelheim (which markets alteplase outside of North America)
during the conduct of the study. Prof. Demchuk reports per-
sonal fees from Medtronic, personal fees from Daiichi Sankyo,
and a patent to Circle NVI issued outside the submitted work.
Prof. Lindley reports grants from NHMRC of Australia during
the conduct of the study. Dr. Mair reports grants from The
Stroke Association, UK, during the conduct of the study. Prof.
Wardlaw reports grants from The Stroke Association, UK, the
Fondation Leducq, the British Heart Foundation, The Euro-
pean Union, the Row Fogo Charitable Trust, the Alzheimer’s
Society, Alzheimer’s Research UK, and UK Medical Research
Council during the conduct of the study. Prof. Anderson
reports receiving honorarium from Takeda during the conduct
of the study. Other authors have nothing to disclose for the
present study. Go to Neurology.org/N for full disclosures.
Publication History






The George Institute for
Global Health, Australia;
and Ren Ji Hospital, School















The George Institute for
Global Health, Australia
Major role in the
acquisition of data,
interpreted the data,




The George Institute for
Global Health, Australia
Major role in the
acquisition of data,
interpreted the data,





The George Institute for
Global Health, Australia
Major role in the






The George Institute for
Global Health, Australia
Major role in the







The George Institute for
Global Health, Australia
Major role in the









Major role in the






The George Institute for
Global Health, Australia
Major role in the







The George Institute for
Global Health, Australia
Major role in the






The George Institute for
Global Health, Australia
Interpreted the data,














The George Institute for
Global Health, Australia
Interpreted the data,











revised the manuscript for
intellectual content
Continued
Neurology.org/N Neurology | Volume 96, Number 11 | March 16, 2021 e1525
References
1. Hsia AW, Sachdev HS, Tomlinson J, et al. Efficacy of IV tissue plasminogen activator
in acute stroke: does stroke subtype really matter? Neurology 2003;61:71–75.
2. Fuentes B, Mart́ınez-Sánchez P, Alonso de Leciñana M, et al. Efficacy of intravenous
thrombolysis according to stroke subtypes: the Madrid Stroke Network data. Eur J
Neurol 2012;19:1568–1574.
3. Mustanoja S, Meretoja A, Putaala J, et al. Outcome by stroke etiology in patients
receiving thrombolytic treatment: descriptive subtype analysis. Stroke 2011;42:102–106.
4. Barow E, Boutitie F, Cheng B, et al. Functional outcome of intravenous thrombolysis in
patients with lacunar infarcts in the WAKE-UP trial. JAMA Neurol 2019;76:641–649.
5. Lindley RI, Wardlaw JM, Whiteley WN, et al. Alteplase for acute ischemic stroke:
outcomes by clinically important subgroups in the third International Stroke Trial.
Stroke 2015;46:746–756.
6. Bamford J, Sandercock P, Jones L, et al. The natural history of lacunar infarction: the
Oxfordshire Community Stroke Project. Stroke 1987;18:545–551.
7. Norrving B. Lacunar infarcts: no black holes in the brain are benign. Pract Neurol
2008;8:222–228.
8. Regenhardt RW, Das AS, Lo EH, Caplan LR. Advances in understanding the path-
ophysiology of lacunar stroke: a review. JAMA Neurol 2018;75:1273–1281.
9. Anderson CS, Robinson T, Lindley RI, et al. Low-dose versus standard-dose in-
travenous alteplase in acute ischemic stroke. N Engl J Med 2016;374:2313–2323.
10. Huang Y, Sharma VK, Robinson T, et al. Rationale, design, and progress of the
Enhanced Control of Hypertension and Thrombolysis Stroke Study (ENCHAN-
TED) trial: an international multicenter 2 × 2 quasi-factorial randomized controlled
trial of low- vs. standard-dose rt-PA and early intensive vs. guideline-recommended
blood pressure lowering in patients with acute ischaemic stroke eligible for throm-
bolysis treatment. Int J Stroke 2015;10:778–788.
11. Anderson CS, Woodward M, Arima H, et al. Statistical analysis plan for evaluating
low- vs. standard-dose alteplase in the Enhanced Control of Hypertension and
Thrombolysis Stroke Study (ENCHANTED). Int J Stroke 2015;10:1313–1315.
12. Adams HP Jr, Bendixen BH, Kappelle LJ, et al. Classification of subtype of acute
ischemic stroke: definitions for use in a multicenter clinical trial: TOAST: Trial of Org
10172 in Acute Stroke Treatment. Stroke 1993;24:35–41.
13. Wardlaw JM, Sandercock P, Cohen G, et al. Association between brain imaging signs,
early and late outcomes, and response to intravenous alteplase after acute ischaemic
stroke in the third International Stroke Trial (IST-3): secondary analysis of a rand-
omised controlled trial. Lancet Neurol 2015;14:485–496.
14. Mair G, von Kummer R, Adami A, et al. Arterial obstruction on computed tomo-
graphic or magnetic resonance angiography and response to intravenous thrombo-
lytics in ischemic stroke. Stroke 2017; 48:353–360.
15. Wardlaw JM, Smith EE, Biessels G, et al. Neuroimaging standards for research into
small vessel disease and its contribution to ageing and neurodegeneration. Lancet
Neurol 2013;12:822–838.
16. Arba F, Mair G, Phillips S, et al. Improving clinical detection of acute lacunar stroke:
analysis from the IST-3. Stroke 2020;51:1411–1418.
17. Matusevicius M, Paciaroni M, Caso V, et al. Outcome after intravenous thrombolysis
in patients with acute lacunar stroke: an observational study based on SITS in-
ternational registry and a meta-analysis. Int J Stroke 2019;14:878–886.
18. Zivanovic Z, Gubi M, Vlahovic D, et al. Patients with acute lacunar infarction have
benefit from intravenous thrombolysis. J Stroke Cerebrovasc Dis 2019;28:435–440.
19. Eggers CCJ, Bocksrucker C, Seyfang L, et al. The efficacy of thrombolysis in lacunar
stroke: evidence from the Austrian Stroke Unit Registry. Eur J Neurol 2017;24:780–787.
20. ShobhaN, Fang J, Hill MD. Do lacunar strokes benefit from thrombolysis? Evidence from
the registry of the Canadian Stroke Network. Int J Stroke 2013;8(suppl A100):45–49.
21. Fluri F, Hatz F, Rutgers MP, et al. Intravenous thrombolysis in patients with stroke
attributable to small artery occlusion. Eur J Neurol 2010;17:1054–1060.
22. Makin SD, Doubal FN, Dennis MS, et al. Clinically confirmed stroke with negative
diffusion-weighted imaging magnetic resonance imaging: longitudinal study of clinical
outcomes, stroke recurrence, and systematic review. Stroke 2015;46:3142–3148.
23. Pantoni L, Fierini F, Poggesi A. Thrombolysis in acute stroke patients with cerebral
small vessel disease. Cerebrovasc Dis 2014;37:5–13.
24. Nagaraja N, Forder JR, Warach S, et al. Reversible diffusion-weighted imaging lesions







University of Leicester, UK Designed and
conceptualized study,
interpreted the data,

































University of Edinburgh, UK Interpreted the data,





University of Edinburgh, UK Designed and
conceptualized study,
interpreted the data,















e1526 Neurology | Volume 96, Number 11 | March 16, 2021 Neurology.org/N
DOI 10.1212/WNL.0000000000011598
2021;96;e1512-e1526 Published Online before print February 3, 2021Neurology 
Zien Zhou, Candice Delcourt, Chao Xia, et al. 
ENCHANTED Trial
Low-Dose vs Standard-Dose Alteplase in Acute Lacunar Ischemic Stroke: The




including high resolution figures, can be found at:
References
 http://n.neurology.org/content/96/11/e1512.full#ref-list-1

















its entirety can be found online at:




Information about ordering reprints can be found online:
ISSN: 0028-3878. Online ISSN: 1526-632X.
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.. All rights reserved. Print
1951, it is now a weekly with 48 issues per year. Copyright Copyright © 2021 The Author(s). Published by 
® is the official journal of the American Academy of Neurology. Published continuously sinceNeurology 
